May 20, 2011 (San Diego, CA) — The platelet-function test VerifyNow P2Y12 (Accumetrics), has been granted a CE mark in Europe for a new, updated claim for prognostic use to help identify patients with ...
SAN DIEGO--(BUSINESS WIRE)--Accumetrics, Inc., developer of the VerifyNow ® System, the first rapid and easy-to-use system for measuring platelet reactivity to multiple antiplatelet agents, announced ...
SAN DIEGO, Nov. 19 Accumetrics, Inc., developer of the VerifyNow System, the first point-of-care method for measuring platelet reactivity, announces that its market-leading VerifyNow P2Y12 Test was ...
Accumetrics, Inc., developer of the market-leading VerifyNow® System, announced an expansion in the intended use for the CE marked VerifyNow P2Y12 Test. Physicians can now use the test results to ...
San Francisco, CA - Absolute and relative levels of platelet inhibition based on a VerifyNow test (Accumetrics) are strong independent predictors of stent thrombosis in patients who have undergone ...
Antiplatelet drug therapy has become one of the cornerstones of treatment for patients with cardiovascular disease. Large clinical trials have shown that antiplatelet medications have important ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results